ARDS, COVID-19
Conditions
Keywords
fludrocortisone, mineralocorticoid, COVID-19, ARDS, Aldosterone
Brief summary
There is a considerable variability in aldosterone levels between individuals, and this may explain the wide variability in disease severity among those infected so we designed a pilot study to test for the safety and efficacy of fludrocortisone addition to standard of care in hospitalised COVID-19 patients.
Detailed description
Many studies have shown involvement of renin-angiotensin-aldosterone system (RAAS) in pathophysiology of COVID-19. There is a considerable variability between people infected with SARS-COV-2 virus in terms of severity. At pathophysiological level there are variable degrees of increased capillary permeability with resultant fluid leak. We hypothesize that the physiological response to overcome this fluid leak mainly involves stimulation of mineralocorticoid (aldosterone) pathway. Hence; those with defective mineralocorticoid response are at high risk for disease complications. Aldosterone secretion capacity is affected by many factors whether physiological (age, sex, ethnicity and pregnancy) or pathological (e.g. smoking); this is reflected in wide differences (regarding aldosterone levels) between groups of people depending on these factors. These variations in mineralocorticoid capacity between groups of people may explain why some certain groups are at high risk for severe disease while others are at a lower risk. So we designed this pilot study to assess safety and efficacy of mineralocorticoid, in the form of fludrocortisone, as a potential treatment for COVID-19 by its addition to dexamethasone in hospitalized COVID-19 patients.
Interventions
DRUGFludrocortisone Acetate 0.1 MG
Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
Sponsors
Ain Shams University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and non-pregnant female patients 18 years of age or older * Diagnosed with COVID-19 pneumonia as per local guidelines * Oxygen saturation (SaO2) of 93 % or less while they were breathing ambient air.
Exclusion criteria
* A physician decision that involvement in the trial will not be in the patient's best interest, presence of any condition that would not allow the protocol to be followed safely. * known allergy or hypersensitivity to fludrocortisone. * known severe liver or kidney disease, uncontrolled hypertension, diabetes mellitus and peptic ulcer disease. * Hypokalemia (serum potassium of less than 3.5 mEq/L) * Use of medications that are contraindicated with fludrocortisone and that could not be replaced or stopped during the trial period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to recovery | 28 days | The first day, during the 28 days after enrollment, on which a patient met the criteria for category 1 or 2 on the eight-category ordinal scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of hospital stay | 28 days | Number of days since enrollment till hospital discharge. |
| Rate of ICU admission | 28 days | Number of patients who experienced worsening of clinical status necessitating ICU admission. |
| Mortality Rate | 28 days | All-cause mortality rate over 28 days post enrollment. |
| Improvement of lymphopenia | 7 days | Reversal of lymphopenia - measured at days 3 and 7 after initiation of treatment. |
| Duration of Increased Supplemental Oxygen | 28 days | Number of days counted from enrollment over which the participant requires supplemental oxygen in excess over his/her baseline. |
| Mechanical ventilation need | 28 days | Number of patients who needed invasive mechanical ventilation during hospitalisation. |
Countries
Egypt
Outcome results
None listed